Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Company Overview

Calliditas Therapeutics AB (publ) was a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly conditions affecting the kidneys and liver. The company was headquartered in Stockholm, Sweden, and operated internationally through partnerships and commercial organizations in Europe and the United States.

Calliditas’ lead product was Nefecon, a targeted-release formulation of budesonide developed for adults with primary immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disease. The product was marketed in the United States as Tarpeyo and in the European Union under the name Kinpeygo. Calliditas also pursued additional clinical programs, including therapies aimed at other rare inflammatory and fibrotic diseases.

The company was founded in 2004 as Pharmalink and adopted the Calliditas Therapeutics name in 2018. Renée Aguiar-Lucander served as chief executive officer during the company’s commercialization and international expansion. In 2024, Asahi Kasei Corporation completed its acquisition of Calliditas, and Calliditas subsequently ceased to operate as an independent publicly traded company.

Key Stats

• Today's Range: $40.00 to $40.00
• 50-Day Range: $40.00 to $40.00
• 52-Week Range: $15.25 to $43.00
• Volume: N/A
• Average Volume: 10,339 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/13/2024
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CALT
• CIK: 1795579
• Web: www.calliditas.se
• Phone: 46-0-841-130-05
• Fax: N/A
• Employees: 180
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.96 million
• Net Margins: -30.18%
• Pretax Margin: -29.40%
• Return on Equity: -212.04%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: 9.44
• Current Ratio: 2.69
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $1.60 billion
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 37.74

Miscellaneous

• Outstanding Shares: 29,790,000
• Free Float: 29,135,000
• Market Cap: $1.19 billion
• Optionable: No Data
• Beta: 1.77